China Resources Pharmaceutical Group Limited
CRPGF
$0.5414
$0.54140.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 51.86M | 52.11M | 179.85M | 181.41M | 81.20M |
| Total Depreciation and Amortization | 120.16M | 120.74M | 112.41M | 113.38M | 113.21M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -541.80K |
| Total Other Non-Cash Items | 259.87M | 261.13M | 293.84M | 296.39M | 220.64M |
| Change in Net Operating Assets | 857.86M | 862.00M | -656.52M | -662.21M | 923.35M |
| Cash from Operations | 1.29B | 1.30B | -70.42M | -71.03M | 1.34B |
| Capital Expenditure | -110.63M | -111.17M | -72.70M | -73.33M | -96.53M |
| Sale of Property, Plant, and Equipment | 8.47M | 8.51M | 4.15M | 4.18M | 10.63M |
| Cash Acquisitions | -105.22M | -105.72M | -24.10M | -24.31M | -21.27M |
| Divestitures | -199.20K | -200.20K | -- | -- | 2.76M |
| Other Investing Activities | -169.66M | -170.48M | -146.27M | -147.54M | -57.43M |
| Cash from Investing | -377.24M | -379.06M | -238.93M | -241.00M | -161.83M |
| Total Debt Issued | 16.54B | 16.54B | 23.33B | 23.33B | 16.37B |
| Total Debt Repaid | -22.43B | -22.43B | -20.77B | -20.77B | -23.32B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -103.49M | -103.99M | -- | -- | -60.94M |
| Other Financing Activities | -2.84B | -2.84B | -1.50B | -1.50B | 193.56M |
| Cash from Financing | -1.32B | -1.32B | 146.10M | 147.36M | -996.96M |
| Foreign Exchange rate Adjustments | -2.85M | -2.86M | 396.50K | 400.00K | 21.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -407.82M | -409.80M | -162.85M | -164.26M | 179.09M |